Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension-Reference-Cited by-同舟云学术

Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension

Published:2011-01-18 Issue:3 Volume:27 Page:651-662
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Hyams Jeffrey,Walters Thomas D.,Crandall Wallace,Kugathasan Subra,Griffiths Anne,Blank Marion,Johanns Jewel,Lang Yinghua,Markowitz James,Cohen Stanley,Winter Harland S.,Veereman-Wauters Gigi,Ferry George,Baldassano Robert

Publisher

Informa Healthcare

Subject

General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1185/03007995.2010.547575

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Endoscopic Healing and Durability between Combination Therapy with Infliximab and Azathioprine versus Infliximab Monotherapy in Pediatric Crohn's disease;2024-06-25

2. Infliximab for maintenance of medically-induced remission in Crohn's disease;Cochrane Database of Systematic Reviews;2024-02-19

3. Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project;Pharmacological Research;2024-02

4. Trajectory of body mass index and obesity in children with Crohn's disease compared to healthy children;Journal of Pediatric Gastroenterology and Nutrition;2023-12-10

5. Managing pediatric Crohn’s disease: recent insights;Expert Review of Gastroenterology & Hepatology;2023-10-03